We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 9, 2006
Last Update Posted: June 12, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jung-Hwan Yoon, Seoul National University Hospital
The purpose of this study is to evaluate the effect of serum hepatitis B virus (HBV) DNA level on intrahepatic recurrence in locally treatable hepatocellular carcinomas (HCCs) related with HBV.

Condition Intervention Phase
Carcinoma, Hepatocellular Chronic Hepatitis B Procedure: PEIT Procedure: RFTA Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Cohort Study of the Effect of Serum HBV DNA Level on Intrahepatic Recurrence in Locally Treatable, HBV-related HCC Patients

Resource links provided by NLM:

Further study details as provided by Jung-Hwan Yoon, Seoul National University Hospital:

Primary Outcome Measures:
  • 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) [ Time Frame: 1,3,5 year ]
    The disease free survival is defined as the total number of surviving participants without intrahepatic recurrence of hepatocellular carcinoma for 1, 3, and 5 years.

Secondary Outcome Measures:
  • 1,3,5-year Overall Survival [ Time Frame: 1,3,5-year ]

Enrollment: 145
Study Start Date: October 2006
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: percutaneous ethanol injection therapy
Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
Procedure: PEIT
Percutaneous Ethanol Injection Therapy
Other Name: PEI, local ablation therapy
Active Comparator: radiofrequency thermal ablation
Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
Procedure: RFTA
Radiofrequency Thermal Ablation
Other Name: RFA, local ablation therapy

Detailed Description:

Prospective cohort study


  • Overall survival rate
  • Disease free survival rate


  • Cumulative recurrence rate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Child-Pugh Class A or B
  • Maximal tumor size less than 5 cm
  • No previous history of treatment for hepatocellular carcinoma
  • Recurrent hepatocellular carcinoma located more than 2 cm from the previous cancer site and is found more than 1 year's gap

Exclusion Criteria:

  • Hepatocellular carcinoma in portal vein
  • Hepatocellular carcinoma in hepatic vein
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00397540

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Study Director: Won Kim, Professor Seoul National University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jung-Hwan Yoon, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT00397540     History of Changes
Other Study ID Numbers: 10-2006-001
First Submitted: November 7, 2006
First Posted: November 9, 2006
Results First Submitted: September 22, 2009
Results First Posted: March 15, 2010
Last Update Posted: June 12, 2015
Last Verified: May 2015

Keywords provided by Jung-Hwan Yoon, Seoul National University Hospital:

Additional relevant MeSH terms:
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Disease Attributes
Pathologic Processes
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs